OOIR: Observatory of International Research

Papers

(The TQCC of Molecular Neurodegeneration is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances	558
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease	425
Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease	201
The role of TDP-43 mislocalization in amyotrophic lateral sclerosis	183
Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration	108
Neuropathology and molecular diagnosis of Synucleinopathies	105
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease	105
APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease	104
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies	100
Tauopathies: new perspectives and challenges	98
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics	98
TDP-43 Pathology in Alzheimer’s Disease	97
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis	95
Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease	95
Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery	94
Plaque associated microglia hyper-secrete extracellular vesicles and accelerate tau propagation in a humanized APP mouse model	93
“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies	91
Cellular and pathological heterogeneity of primary tauopathies	90
New approaches to symptomatic treatments for Alzheimer’s disease	90
Microbiota in neuroinflammation and synaptic dysfunction: a focus on Alzheimer’s disease	90
Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry	86
Solving neurodegeneration: common mechanisms and strategies for new treatments	85
METTL3-dependent RNA m6A dysregulation contributes to neurodegeneration in Alzheimer’s disease through aberrant cell cycle events	84
NLRP12 collaborates with NLRP3 and NLRC4 to promote pyroptosis inducing ganglion cell death of acute glaucoma	79
Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: a systematic review of symptom-general and –specific lesion patterns	78

Post-infection cognitive impairments in a cohort of elderly patients with COVID-19	77
Glycosphingolipids and neuroinflammation in Parkinson’s disease	76
Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination	71
Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology	70
Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers	68
P2RX7 inhibitor suppresses exosome secretion and disease phenotype in P301S tau transgenic mice	68
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases	66
Plaque-associated human microglia accumulate lipid droplets in a chimeric model of Alzheimer’s disease	64
Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia	63
Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions	62
Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders	56
Microbial involvement in Alzheimer disease development and progression	55
The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives	53
Constitutively active SARM1 variants that induce neuropathy are enriched in ALS patients	53
Adult-onset CNS myelin sulfatide deficiency is sufficient to cause Alzheimer’s disease-like neuroinflammation and cognitive impairment	52
Impaired NHEJ repair in amyotrophic lateral sclerosis is associated with TDP-43 mutations	52
Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain	51
Dynamic changes of CSF sTREM2 in preclinical Alzheimer’s disease: the CABLE study	50
The Alzheimer’s disease-associated protective Plcγ2-P522R variant promotes immune functions	48
The CD33 short isoform is a gain-of-function variant that enhances Aβ1–42 phagocytosis in microglia	47
The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored	47
CNS axonal degeneration and transport deficits at the optic nerve head precede structural and functional loss of retinal ganglion cells in a mouse model of glaucoma	46
Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach	45
The role of inflammasomes in vascular cognitive impairment	45
Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer’s disease brain	44
The informed road map to prevention of Alzheimer Disease: A call to arms	44
Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis	44
Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson’s disease	43
Clusterin secreted from astrocyte promotes excitatory synaptic transmission and ameliorates Alzheimer’s disease neuropathology	43
Identification of sixteen novel candidate genes for late onset Parkinson’s disease	42
A novel systems biology approach to evaluate mouse models of late-onset Alzheimer’s disease	42
Alzheimer’s disease – the journey of a healthy brain into organ failure	42
Trem2 deficiency differentially affects phenotype and transcriptome of human APOE3 and APOE4 mice	42
Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer’s disease mutations but not by inhibition of BACE1	41
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application	40
FRET-based Tau seeding assay does not represent prion-like templated assembly of Tau filaments	40
Cholesterol alters mitophagy by impairing optineurin recruitment and lysosomal clearance in Alzheimer’s disease	39
Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM2	38
CX3CR1 deficiency aggravates amyloid driven neuronal pathology and cognitive decline in Alzheimer’s disease	38
TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target	37
Flow-cytometric microglial sorting coupled with quantitative proteomics identifies moesin as a highly-abundant microglial protein with relevance to Alzheimer’s disease	37
Deciphering cellular transcriptional alterations in Alzheimer’s disease brains	36
Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis	35
APOΕ4 lowers energy expenditure in females and impairs glucose oxidation by increasing flux through aerobic glycolysis	35
Modeling the β-secretase cleavage site and humanizing amyloid-beta precursor protein in rat and mouse to study Alzheimer’s disease	35
Trem2 deletion enhances tau dispersion and pathology through microglia exosomes	35
Enhancing GABAergic signaling ameliorates aberrant gamma oscillations of olfactory bulb in AD mouse models	35
Sex-dependent calcium hyperactivity due to lysosomal-related dysfunction in astrocytes from APOE4 versus APOE3 gene targeted replacement mice	35
Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain	34
The landscape of human tissue and cell type specific expression and co-regulation of senescence genes	34

Adiponectin-mimetic novel nonapeptide rescues aberrant neuronal metabolic-associated memory deficits in Alzheimer’s disease	33
Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer’s disease	33
α-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment	32
Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration	32
Sleep and circadian rhythms in Parkinson’s disease and preclinical models	32
Tauopathy-associated tau modifications selectively impact neurodegeneration and mitophagy in a novel C. elegans single-copy transgenic model	31
BIN1 protein isoforms are differentially expressed in astrocytes, neurons, and microglia: neuronal and astrocyte BIN1 are implicated in tau pathology	30
From basic research to the clinic: innovative therapies for ALS and FTD in the pipeline	30
Altered network properties in C9ORF72 repeat expansion cortical neurons are due to synaptic dysfunction	30
Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo	28
Parkinson mice show functional and molecular changes in the gut long before motoric disease onset	28
BIN1 is a key regulator of proinflammatory and neurodegeneration-related activation in microglia	28
LRP1 is a neuronal receptor for α-synuclein uptake and spread	28
AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma	28
Basal lamina changes in neurodegenerative disorders	28
Human iPSC-derived astrocytes transplanted into the mouse brain undergo morphological changes in response to amyloid-β plaques	28
Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories	28